FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $371 | -55.5% | 175 | 0.0% | 0.00% | – |
Q2 2023 | $833 | -16.5% | 175 | 0.0% | 0.00% | – |
Q1 2023 | $998 | -43.5% | 175 | 0.0% | 0.00% | – |
Q4 2022 | $1,766 | -55.8% | 175 | 0.0% | 0.00% | -100.0% |
Q3 2022 | $4,000 | 0.0% | 175 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $4,000 | -42.9% | 175 | 0.0% | 0.00% | -50.0% |
Q1 2022 | $7,000 | -30.0% | 175 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $10,000 | 0.0% | 175 | 0.0% | 0.00% | 0.0% |
Q3 2021 | $10,000 | -33.3% | 175 | 0.0% | 0.00% | -33.3% |
Q2 2021 | $15,000 | +7.1% | 175 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $14,000 | -12.5% | 175 | 0.0% | 0.00% | -25.0% |
Q4 2020 | $16,000 | +128.6% | 175 | 0.0% | 0.00% | +100.0% |
Q3 2020 | $7,000 | +16.7% | 175 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $6,000 | +50.0% | 175 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $4,000 | +33.3% | 175 | 0.0% | 0.00% | +100.0% |
Q4 2019 | $3,000 | -81.2% | 175 | -82.5% | 0.00% | -88.9% |
Q3 2019 | $16,000 | -83.5% | 1,000 | -93.5% | 0.01% | -83.0% |
Q2 2014 | $97,000 | – | 15,384 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |